Cargando…

Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy

Oculopharyngeal muscular dystrophy (OPMD) is a rare muscle disease characterized by an onset of weakness in the pharyngeal and eyelid muscles. The disease is caused by the extension of a polyalanine tract in the Poly(A) Binding Protein Nuclear 1 (PABPN1) protein leading to the formation of intranucl...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Fanny, Dhiab, Jamila, Boulinguiez, Alexis, Mouigni, Hadidja-Rose, Lassche, Saskia, Negroni, Elisa, Muraine, Laura, Marhic, Alix, Oliver, Alison, Lainé, Jeanne, Rouche, Andrée, O’Ferrall, Erin K., van Engelen, Baziel, Ottenheijm, Coen, Greif, Hagar, Blumen, Sergiu, Lacau St Guily, Jean, Perie, Sophie, Butler-Browne, Gillian, Mouly, Vincent, Trollet, Capucine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637588/
https://www.ncbi.nlm.nih.gov/pubmed/36197469
http://dx.doi.org/10.1007/s00401-022-02503-7
_version_ 1784825219365470208
author Roth, Fanny
Dhiab, Jamila
Boulinguiez, Alexis
Mouigni, Hadidja-Rose
Lassche, Saskia
Negroni, Elisa
Muraine, Laura
Marhic, Alix
Oliver, Alison
Lainé, Jeanne
Rouche, Andrée
O’Ferrall, Erin K.
van Engelen, Baziel
Ottenheijm, Coen
Greif, Hagar
Blumen, Sergiu
Lacau St Guily, Jean
Perie, Sophie
Butler-Browne, Gillian
Mouly, Vincent
Trollet, Capucine
author_facet Roth, Fanny
Dhiab, Jamila
Boulinguiez, Alexis
Mouigni, Hadidja-Rose
Lassche, Saskia
Negroni, Elisa
Muraine, Laura
Marhic, Alix
Oliver, Alison
Lainé, Jeanne
Rouche, Andrée
O’Ferrall, Erin K.
van Engelen, Baziel
Ottenheijm, Coen
Greif, Hagar
Blumen, Sergiu
Lacau St Guily, Jean
Perie, Sophie
Butler-Browne, Gillian
Mouly, Vincent
Trollet, Capucine
author_sort Roth, Fanny
collection PubMed
description Oculopharyngeal muscular dystrophy (OPMD) is a rare muscle disease characterized by an onset of weakness in the pharyngeal and eyelid muscles. The disease is caused by the extension of a polyalanine tract in the Poly(A) Binding Protein Nuclear 1 (PABPN1) protein leading to the formation of intranuclear inclusions or aggregates in the muscle of OPMD patients. Despite numerous studies stressing the deleterious role of nuclear inclusions in cellular and animal OPMD models, their exact contribution to human disease is still unclear. In this study, we used a large and unique collection of human muscle biopsy samples to perform an in-depth analysis of PABPN1 aggregates in relation to age, genotype and muscle status with the final aim to improve our understanding of OPMD physiopathology. Here we demonstrate that age and genotype influence PABPN1 aggregates: the percentage of myonuclei containing PABPN1 aggregates increases with age and the chaperone HSP70 co-localize more frequently with PABPN1 aggregates with a larger polyalanine tract. In addition to the previously described PRMT1 and HSP70 co-factors, we identified new components of PABPN1 aggregates including GRP78/BiP, RPL24 and p62. We also observed that myonuclei containing aggregates are larger than myonuclei without. When comparing two muscles from the same patient, a similar amount of aggregates is observed in different muscles, except for the pharyngeal muscle where fewer aggregates are observed. This could be due to the peculiar nature of this muscle which has a low level of PAPBN1 and contains regenerating fibers. To confirm the fate of PABPN1 aggregates in a regenerating muscle, we generated a xenograft model by transplanting human OPMD muscle biopsy samples into the hindlimb of an immunodeficient mouse. Xenografts from subjects with OPMD displayed regeneration of human myofibers and PABPN1 aggregates were rapidly present—although to a lower extent-after muscle fiber regeneration. Our data obtained on human OPMD samples add support to the dual non-exclusive models in OPMD combining toxic PABPN1 intranuclear inclusions together with PABPN1 loss of function which altogether result in this late-onset and muscle selective disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00401-022-02503-7.
format Online
Article
Text
id pubmed-9637588
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96375882022-11-08 Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy Roth, Fanny Dhiab, Jamila Boulinguiez, Alexis Mouigni, Hadidja-Rose Lassche, Saskia Negroni, Elisa Muraine, Laura Marhic, Alix Oliver, Alison Lainé, Jeanne Rouche, Andrée O’Ferrall, Erin K. van Engelen, Baziel Ottenheijm, Coen Greif, Hagar Blumen, Sergiu Lacau St Guily, Jean Perie, Sophie Butler-Browne, Gillian Mouly, Vincent Trollet, Capucine Acta Neuropathol Original Paper Oculopharyngeal muscular dystrophy (OPMD) is a rare muscle disease characterized by an onset of weakness in the pharyngeal and eyelid muscles. The disease is caused by the extension of a polyalanine tract in the Poly(A) Binding Protein Nuclear 1 (PABPN1) protein leading to the formation of intranuclear inclusions or aggregates in the muscle of OPMD patients. Despite numerous studies stressing the deleterious role of nuclear inclusions in cellular and animal OPMD models, their exact contribution to human disease is still unclear. In this study, we used a large and unique collection of human muscle biopsy samples to perform an in-depth analysis of PABPN1 aggregates in relation to age, genotype and muscle status with the final aim to improve our understanding of OPMD physiopathology. Here we demonstrate that age and genotype influence PABPN1 aggregates: the percentage of myonuclei containing PABPN1 aggregates increases with age and the chaperone HSP70 co-localize more frequently with PABPN1 aggregates with a larger polyalanine tract. In addition to the previously described PRMT1 and HSP70 co-factors, we identified new components of PABPN1 aggregates including GRP78/BiP, RPL24 and p62. We also observed that myonuclei containing aggregates are larger than myonuclei without. When comparing two muscles from the same patient, a similar amount of aggregates is observed in different muscles, except for the pharyngeal muscle where fewer aggregates are observed. This could be due to the peculiar nature of this muscle which has a low level of PAPBN1 and contains regenerating fibers. To confirm the fate of PABPN1 aggregates in a regenerating muscle, we generated a xenograft model by transplanting human OPMD muscle biopsy samples into the hindlimb of an immunodeficient mouse. Xenografts from subjects with OPMD displayed regeneration of human myofibers and PABPN1 aggregates were rapidly present—although to a lower extent-after muscle fiber regeneration. Our data obtained on human OPMD samples add support to the dual non-exclusive models in OPMD combining toxic PABPN1 intranuclear inclusions together with PABPN1 loss of function which altogether result in this late-onset and muscle selective disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00401-022-02503-7. Springer Berlin Heidelberg 2022-10-05 2022 /pmc/articles/PMC9637588/ /pubmed/36197469 http://dx.doi.org/10.1007/s00401-022-02503-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Roth, Fanny
Dhiab, Jamila
Boulinguiez, Alexis
Mouigni, Hadidja-Rose
Lassche, Saskia
Negroni, Elisa
Muraine, Laura
Marhic, Alix
Oliver, Alison
Lainé, Jeanne
Rouche, Andrée
O’Ferrall, Erin K.
van Engelen, Baziel
Ottenheijm, Coen
Greif, Hagar
Blumen, Sergiu
Lacau St Guily, Jean
Perie, Sophie
Butler-Browne, Gillian
Mouly, Vincent
Trollet, Capucine
Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
title Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
title_full Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
title_fullStr Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
title_full_unstemmed Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
title_short Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
title_sort assessment of pabpn1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637588/
https://www.ncbi.nlm.nih.gov/pubmed/36197469
http://dx.doi.org/10.1007/s00401-022-02503-7
work_keys_str_mv AT rothfanny assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT dhiabjamila assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT boulinguiezalexis assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT mouignihadidjarose assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT lasschesaskia assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT negronielisa assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT murainelaura assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT marhicalix assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT oliveralison assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT lainejeanne assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT roucheandree assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT oferrallerink assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT vanengelenbaziel assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT ottenheijmcoen assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT greifhagar assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT blumensergiu assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT lacaustguilyjean assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT periesophie assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT butlerbrownegillian assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT moulyvincent assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy
AT trolletcapucine assessmentofpabpn1nuclearinclusionsonalargecohortofpatientsandinahumanxenograftmodelofoculopharyngealmusculardystrophy